ABOUT THIS EPISODE
EP Edge® Journal Watch | Issue 40 | October 2026
Beyond AF Burden: Stroke Risk, Rhythm Progression, Atrial Pacing, and Sudden Death Prevention
Should oral anticoagulation continue after successful atrial fibrillation ablation? Does AF density provide better stroke-risk information than conventional burden measurements? Can the GLORIA-AF score improve thromboembolic risk prediction? And could autonomic modulation or advances in pacing and defibrillator therapy change electrophysiology practice?
In Issue 40 of EP Edge® Journal Watch, Dr. Sharma examines eleven research papers, with detailed analysis of five major studies and concise reviews of six additional publications.
The episode explores study methodology, statistical interpretation, clinical relevance, and the distinction between promising associations and evidence sufficient to change practice.
Featured Studies
1. Anticoagulation After AF Ablation | Ren et al.
A prospective observational analysis of 13,669 patients examines continuation versus discontinuation of oral anticoagulation following catheter ablation.
Continued anticoagulation after six months was not associated with a statistically significant reduction in thromboembolism across stroke-risk categories, while major bleeding was higher in anticoagulated high-risk patients. The interpretation is complicated by nonrandom treatment selection, differences in baseline stroke risk, and incomplete quantitative AF burden assessment.
We discuss adjusted hazard ratios, absolute event rates, confidence intervals, confounding by indication, and the implications of contemporary randomized evidence, including ALONE-AF, OCEAN, and OPTION.
The accompanying editorial by Alhassan and Kwaku provides additional context for individualized anticoagulation strategies after ablation.
Ren et al. DOI:
https://doi.org/10.1161/JAHA.125.047527
2. AF Density and Ischemic Stroke | Rosman et al.
Can the temporal clustering of atrial fibrillation episodes improve stroke prediction beyond total AF burden?
This observational study of 12,868 patients with implanted cardiac monitors evaluates AF density, a measure of how concentrated or dispersed arrhythmia episodes are over time.
Higher AF density was associated with greater modeled ischemic stroke risk, even when cumulative AF burden was considered.
We examine the parametric g-formula, adjustment for time-varying covariates, competing risks, and why a prognostic association does not establish a treatment threshold for anticoagulation.
Rosman et al. DOI:
https://doi.org/10.1093/eurheartj/ehag203
3. GLORIA-AF Stroke Weighted Risk Score | Xie et al.
A new weighted stroke-risk score incorporating ten routinely available clinical variables is developed in 20,517 patients and externally validated in 8,309 patients from European and Asia-Pacific AF registries.
The score demonstrated statistically better stroke discrimination than CHA₂DS₂-VA, with external validation C-index values of 0.652 versus 0.616.
We examine discrimination, calibration, integrated discrimination improvement, net reclassification improvement, and decision-curve analysis.
A central question is whether better statistical prediction produces sufficiently meaningful improvement to influence anticoagulation decisions, particularly when many patients in the derivation cohort were already anticoagulated.
Xie et al. DOI:
https://doi.org/10.1093/europace/euag236
4. Stellate Ganglion Block and Postoperative AF | Tian et al.
A randomized controlled trial evaluates preemptive ultrasound-guided left stellate ganglion block in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.
Among 108 patients in the modified intention-to-treat analysis, postoperative AF occurred in 18.5% of the intervention group versus 44.4% of controls.
We examine the absolute risk reduction, odds ratio, exploratory number needed to treat, perioperative beta-blocker use, incomplete inclusion of randomized participants, absence of a sham procedure, and limitations of short-term follow-up.
The study raises important questions about autonomic modulation as a preventive strategy, but larger multicenter trials are required before routine clinical adoption.
Tian et al. DOI:
https://doi.org/10.1016/j.jacep.2026.07.006
5. ICD Therapy in Hypertrophic Cardiomyopathy | Rowin et al.
An international study from 25 centers examines long-term implantable cardioverter-defibrillator outcomes in 3,387 patients with hypertrophic cardiomyopathy.
Appropriate device therapy occurred in 16% of patients overall, including 15% of primary-prevention recipients.
Among primary-prevention patients who experienced appropriate device therapy, 16% received their first intervention at least ten years after implantation.
We explore appropriate device interventions, late ventricular arrhythmias, clinical risk markers, sudden cardiac death, and the distinction between an appropriate ICD intervention and a death that would certainly have occurred without treatment.
The study provides valuable evidence about long-term device performance and the continued importance of individualized sudden-death risk assessment.
Rowin et al. DOI:
https://doi.org/10.1161/CIRCULATIONAHA.125.078597
Additional Research Covered
6. Device-Detected Atrial High-Rate Episodes | Botto et al.
Does a daily atrial high-rate episode burden of at least six minutes identify patients at increased risk of cardiovascular death, worsening heart failure hospitalization, or stroke?
This post hoc analysis of 1,160 patients from the B3 randomized pacing trial found a strong association with composite cardiovascular outcomes among patients without previously diagnosed AF.
The association was driven mainly by worsening heart failure hospitalization and cardiovascular death, rather than a statistically significant increase in stroke or transient ischemic attack.
The results emphasize the broader prognostic implications of device-detected atrial arrhythmias while highlighting the limitations of observational subgroup analyses.
Botto et al. DOI:
https://doi.org/10.1016/j.hrthm.2026.02.048
7. Progression of Persistent AF | Thakur et al.
A systematic review and meta-analysis evaluates progression from persistent to permanent atrial fibrillation, reporting a pooled progression rate of 16.42 per 100 person-years.
Substantial between-study heterogeneity and differences in the definition of permanent AF complicate interpretation.
The analysis also explores whether greater exposure to pulmonary vein isolation is associated with lower progression rates, while emphasizing that study-level associations do not establish causal treatment effects.
Thakur et al. DOI:
https://doi.org/10.1016/j.hrthm.2026.04.012
8. Predictors of Recurrence After AF Ablation | Chan et al.
<...
